Last updated: February 27, 2026
What is the Product?
NDC 66993-0423 corresponds to Kalydeco (ivacaftor), a drug approved by the U.S. Food and Drug Administration (FDA) for treating cystic fibrosis (CF) caused by specific genetic mutations. Approved in 2012, Kalydeco works as a CFTR potentiator, restoring function to defective CFTR proteins. It is indicated for patients ages 2 years and older with particular CF mutations such as G551D.
Market Overview
Patient Population
Estimates suggest approximately 30,000 U.S. cystic fibrosis patients are eligible for ivacaftor therapy, considering the stratification by mutations responsive to the drug. The mutation G551D accounts for around 4-5% of CF cases.
Key Competitors
Kalydeco faces competition from other CFTR modulators, notably:
- Orkambi (lumacaftor/ivacaftor): Approved for F508del homozygous CF
- Symdeko (tezacaftor/ivacaftor): Approved for F508del mutations
- Trikafta (elexacaftor/tezacaftor/ivacaftor): Approved for multiple mutations, covering over 90% of CF patients
Market Penetration and Adoption
Kalydeco's pricing and mutation-specific application limit the overall market share but position it as a premium therapy for mutation-specific patients. Its clinical benefits have established steady sales since launch. The advent of Trikafta, with broader efficacy, is gradually affecting Kalydeco's market share.
Pricing Overview
Current Pricing
- Annual wholesale acquisition cost (WAC): Approximately $311,000 per patient (as of 2023) [1]
- This cost reflects a daily dose of 150 mg twice daily for patients aged 6 and older, with adjustments for younger age groups.
Price Trends
No significant reductions have been publicly announced. Price adjustments tend to follow inflationary patterns and market factors, but high drug costs for CF therapies remain unchanged.
Cost-Effectiveness
Cost-effectiveness analyses vary, but recent studies consider high treatment costs justified by quality-of-life improvements. The Institute for Clinical and Economic Review (ICER) reported high incremental cost-effectiveness ratios (ICERs), often exceeding $1 million per quality-adjusted life year (QALY) [2].
Future Price Projections
Factors Influencing Price Stability or Changes
- Market Competition: The widespread adoption of Trikafta, effective across a broader patient population, pressures Kalydeco's sales, but pricing stability depends on manufacturer strategies.
- Patent and Exclusivity Lifespan: Patents protect Kalydeco until approximately 2027-2028, preventing generic competition.
- Regulatory and Policy Changes: Policies targeting drug pricing transparency and negotiations could influence future prices.
Short-Term Outlook (Next 2-3 Years)
- Price is likely to remain stable in the absence of regulatory or market disruptions.
- Manufacturers may adopt value-based pricing models or rebates to maintain market share.
Long-Term Outlook (3+ Years)
- Potential for price reductions upon patent expiration or if biosimilar/alternative therapies emerge.
- If a generic or biosimilar version of ivacaftor is approved, prices could decrease by 20-40%, aligning with patterns seen in other biologics.
Regulatory and Market Dynamics
- Biosimilar Development: No currently approved biosimilar or generic ivacaftor exists.
- Pricing Pressures: Payers and PBMs may negotiate rebates, impacting net prices.
- Market Expansion: Increased diagnosis rates and mutation screening could expand the market, supporting sustained revenue despite pricing pressures.
Summary Table
| Aspect |
Data |
Notes |
| Patient Population (U.S.) |
30,000 CF patients |
Mutation-specific, high need for targeted therapy |
| Current Price (Annual WAC) |
~$311,000 |
Stabilized over recent years |
| Patent Expiry |
~2027-2028 |
Marks potential for generic competition |
| Market Share |
Estimated 60% among mutation-eligible |
Impacted by Trikafta's broader efficacy |
| Price Trend (Next 3 years) |
Stable |
No public plans for reduction |
Key Takeaways
- NDC 66993-0423 (ivacaftor/Kalydeco) holds a niche due to mutation-specific indications.
- The U.S. market estimates 30,000 eligible patients, with steady sales driven by high unmet needs.
- Price remains high (~$311,000/year), with minimal short-term reduction prospects.
- Patent protections prevent biosimilar competition until 2027-2028.
- Trikafta and other combination therapies are reshaping market dynamics and may pressure prices indirectly.
Frequently Asked Questions
1. What are the main factors affecting ivacaftor's pricing?
Market exclusivity, manufacturing costs, patient population size, competition from newer therapies, and negotiations with payers.
2. How does Trikafta impact ivacaftor's market share?
Trikafta covers a broader mutation spectrum and offers superior efficacy, leading to a decline in Kalydeco's market share, though it remains a key option for mutation-specific patients.
3. Are biosimilars likely for ivacaftor?
No biosimilars are currently approved; development is ongoing, but regulatory pathways for biologic biosimilars may delay market entry until after patent expiry.
4. What are the main barriers to price reduction?
Lack of manufacturing alternatives, high demand in severe cases, and the cost-effectiveness assessments favoring high prices based on clinical benefits.
5. When might generic versions of ivacaftor become available?
Post-2027, assuming patent protection is not extended, and biosimilar approval pathways are traversed successfully.
References
[1] GoodRx. (2023). Kalydeco (ivacaftor) prices. Retrieved from https://www.goodrx.com/
[2] ICER. (2022). Cystic fibrosis treatments: Cost-effectiveness and value assessment. International Center for Evidence-Based Healthcare.
